tradingkey.logo
tradingkey.logo

Cytomx’S Varsetatug Masetecan (Epcam Probody® Adc) Continues To Demonstrate Positive Data Supporting Potential As A New Treatment Option In Late-Line Colorectal Cancer

ReutersMar 16, 2026 11:40 AM

- CytomX Therapeutics Inc CTMX.O:

  • CYTOMX’S VARSETATUG MASETECAN (EPCAM PROBODY® ADC) CONTINUES TO DEMONSTRATE POSITIVE DATA SUPPORTING POTENTIAL AS A NEW TREATMENT OPTION IN LATE-LINE COLORECTAL CANCER

  • CYTOMX THERAPEUTICS INC - PHASE 1 STUDY WITH BEVACIZUMAB INITIATED; PHASE 1B/2 CHEMOTHERAPY COMBINATION STUDY TO START BY END 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI